Baidu
map

J Exp Med:揭示促甲状腺激素加重血管炎症和动脉粥样硬化形成新机制

2019-04-05 辉宏俊 iNature

甲状腺功能减退症(hypothyroidism,简称甲减),是多种原因引起的甲状腺激素(TH)合成、分泌或生物效应不足所致的一组内分泌疾病,仅有血清促甲状腺激素(TSH)水平轻度升高,而血清甲状腺激素(FT4,FT3)水平正常,患者无甲减症状或仅有轻微甲减症状,称为亚临床甲状腺功能减退症(subclinical hypothyroidism,简称亚临床甲减),又称为轻微型甲减,潜伏期型甲减、生化性

甲状腺功能减退症(hypothyroidism,简称甲减),是多种原因引起的甲状腺激素(TH)合成、分泌或生物效应不足所致的一组内分泌疾病,仅有血清促甲状腺激素(TSH)水平轻度升高,而血清甲状腺激素(FT4,FT3)水平正常,患者无甲减症状或仅有轻微甲减症状,称为亚临床甲状腺功能减退症(subclinical hypothyroidism,简称亚临床甲减),又称为轻微型甲减,潜伏期型甲减、生化性甲减和甲状腺储量减少。亚临床甲状腺功能减退症与血管疾病相关,但其潜在机制仍大部分未知。

近日,由山东大学赵家军、张群业团队在JEM上发表了题为“Thyrotropin aggravates atherosclerosis bypromoting macrophage inflammation in plaques”的研究论文。研究结果阐明了促甲状腺激素作为动脉粥样硬化的独立危险因素,加重血管炎症和促进动脉粥样硬化形成的新机制。

甲状腺功能减退被公认为伴有高胆固醇血症和心血管疾病。传统上,这归因于这些患者甲状腺激素水平下降。然而,在亚临床甲状腺功能减退患者中也发现高胆固醇血症和心血管疾病(包括动脉粥样硬化)的风险增加,这些患者的甲状腺激素水平保持正常,只有促甲状腺素水平增加。这表明促甲状腺激素也可能在动脉粥样硬化中发挥作用,与它对甲状腺激素的影响无关。

促甲状腺激素,又称促甲状腺素,是一种由垂体合成和分泌的糖蛋白激素,因其在下丘脑-垂体-甲状腺轴中刺激甲状腺激素合成和分泌的经典作用而闻名。仅仅几十年前,人们发现TSH受体(TSHR)在除甲状腺细胞之外的多种细胞中表达,如肝细胞、脂肪细胞和破骨细胞。这表明促甲状腺激素的功能不仅限于调节甲状腺功能。另一方面,TSHR也被报道在巨噬细胞、内皮细胞和平滑肌细胞中表达。这三种类型的细胞与动脉粥样硬化关系最为密切。因此,促甲状腺激素不仅可以通过调节甲状腺功能间接促进动脉粥样硬化,而且可以直接作用于这些细胞。

为了检验上述假设,在一项横断面人群研究中首先分析了促甲状腺激素和动脉粥样硬化之间的关系。人群中动脉粥样硬化的等级通过超声测量颈动脉内膜中层厚度(CIMT)来监测,这是一种简单、无创的方法,非常适合在大规模人群研究中评估动脉粥样硬化。TSH和动脉粥样硬化之间的因果关系随后用TShr/ApoE/双敲除小鼠进行了证明。此外,体外研究揭示了TSH对巨噬细胞的新促炎作用,其病理生理学意义通过骨髓特异性Tshr缺陷ApoE小鼠得到进一步证实。研究提供了对明显甲状腺功能减退症和自发性高血压易患动脉粥样硬化的机理见解,并提出了先前未被认识到的促炎症和致动脉粥样硬化的促甲状腺激素作用。

原始出处:

Chongbo Yang,et al.Thyrotropin aggravates atherosclerosis by promoting macrophage inflammation in plaques.J Exp Med. 2019 Apr 2. pii: jem.20181473.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944590, encodeId=f72c194459039, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 13 01:59:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263219, encodeId=4d891263219d9, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360277, encodeId=06da13602e730, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479172, encodeId=cd5814e9172c3, content=<a href='/topic/show?id=5d67896914c' target=_blank style='color:#2F92EE;'>#血管炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89691, encryptionId=5d67896914c, topicName=血管炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a47497019, createdName=ms6832696159214430, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609680, encodeId=1f811609680d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1944590, encodeId=f72c194459039, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 13 01:59:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263219, encodeId=4d891263219d9, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360277, encodeId=06da13602e730, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479172, encodeId=cd5814e9172c3, content=<a href='/topic/show?id=5d67896914c' target=_blank style='color:#2F92EE;'>#血管炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89691, encryptionId=5d67896914c, topicName=血管炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a47497019, createdName=ms6832696159214430, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609680, encodeId=1f811609680d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1944590, encodeId=f72c194459039, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 13 01:59:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263219, encodeId=4d891263219d9, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360277, encodeId=06da13602e730, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479172, encodeId=cd5814e9172c3, content=<a href='/topic/show?id=5d67896914c' target=_blank style='color:#2F92EE;'>#血管炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89691, encryptionId=5d67896914c, topicName=血管炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a47497019, createdName=ms6832696159214430, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609680, encodeId=1f811609680d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1944590, encodeId=f72c194459039, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 13 01:59:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263219, encodeId=4d891263219d9, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360277, encodeId=06da13602e730, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479172, encodeId=cd5814e9172c3, content=<a href='/topic/show?id=5d67896914c' target=_blank style='color:#2F92EE;'>#血管炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89691, encryptionId=5d67896914c, topicName=血管炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a47497019, createdName=ms6832696159214430, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609680, encodeId=1f811609680d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1944590, encodeId=f72c194459039, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 13 01:59:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263219, encodeId=4d891263219d9, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360277, encodeId=06da13602e730, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479172, encodeId=cd5814e9172c3, content=<a href='/topic/show?id=5d67896914c' target=_blank style='color:#2F92EE;'>#血管炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89691, encryptionId=5d67896914c, topicName=血管炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a47497019, createdName=ms6832696159214430, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609680, encodeId=1f811609680d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 07 00:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]

相关资讯

AACE 2016:左旋甲状腺素治疗甲状腺功能减退症或可改为每周一次用药

左旋甲状腺素从从每日一次切换到每周一次(剂量为每日剂量的7倍量)可有效治疗女性的甲状腺功能减退症,实现甲状腺功能。古尔加翁公园医院的Satish C. Wasoori博士和同事对40名25-55岁长期甲状腺功能减退(至少5年)的女性进行了研究,这些患者目前服用每日剂量的左旋甲状腺素,评估切换到每周一次(剂量为每日剂量的7倍量)对甲状腺功能减退症的疗效。参与者被分为两组:1组(n = 20),TSH

NEJM:甲状腺功能减退症所致的Woltman征-病例报道

Woltman征是指深部肌腱反射延迟松弛阶段,是甲状腺功能减退症的神经系统表现。这种延迟的放松也可能与怀孕、神经性厌食症、糖尿病和高龄有关。

NEJM:甲状腺功能减退症引起的脆性指甲和脱发-病例报道

甲状腺功能减退症应该与增厚和脆弱的指甲和脱发进行鉴别诊断,尽管这种极端的表现是非典型的。

JCEM:甲状腺功能减退症与全因死亡率的关联

由此可见,甲状腺功能减退与老年人全因死亡率增加独立相关。在甲状腺功能减退症患者中,TRT与全因死亡风险较低相关。

2016SIE/AIT建议——应用左旋甲状腺素和左旋三碘甲状腺氨酸治疗甲状腺功能减退症发布

2016年7月,意大利内分泌学会(SIE)联合意大利甲状腺协会(AIT)共同发布了应用左旋甲状腺素和左旋三碘甲状腺氨酸治疗甲状腺功能减退症的临床建议,左旋甲状腺素(L-T4)建议作为甲状腺功能减退症的终生替代治疗药物,近期临床和实验数据支持添加左旋三碘甲状腺氨酸(L-T3)治疗一些特定的加减患者,本文的主要目的是为甲减患者联合应用L-T4和L-T3治疗定义正确的临床适应症,安排表,持续治疗时间和配

成人甲状腺功能减退症诊治指南

甲状腺功能减退症(hypothyroidism,简称甲减)是由于甲状腺激素合成和分泌减少或组织作用减弱导致的全身代谢减低综合征。主要分为临床甲减(overt hypothyroidism)和亚临床甲减(subclinical hypothyroidism)。甲减的患病率与TSH诊断切点值、年龄、性别、种族等因素有关。

Baidu
map
Baidu
map
Baidu
map